tradingkey.logo

Foresee Completes Phase 3 CASPPIAN Trial Enrollment For Central Precocious Puberty

ReutersJun 17, 2025 10:03 AM

- Foresee Pharmaceuticals Co Ltd 6576.TWO:

  • FORESEE PHARMACEUTICALS ANNOUNCES REACHING A SIGNIFICANT MILESTONE, OF COMPLETE ENROLLMENT OF ITS PHASE 3 CASPPIAN TRIAL FOR PATIENTS WITH CENTRAL PRECOCIOUS PUBERTY (CPP)

  • FORESEE PHARMACEUTICALS CO LTD - TOPLINE RESULTS FROM PHASE 3 CASPPIAN TRIAL EXPECTED BY END OF 2025

  • FORESEE PHARMACEUTICALS CO LTD - PLANS NDA SUBMISSION BY Q3 2026 BASED ON STUDY OUTCOMES

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI